secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001770121-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M
--------------------------------------------------------------------------------

- Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.
- Cash, cash equivalents & securities $72.7M at June 30; pro forma $177.2M including $105M raised in July/August 2025.
- Six-month data show transplanted HIP-edited islet cells survive & function (C-peptide+) without immunosuppression; NEJM published 12-week results.
- Expect to file IND for SC451 (iPSC-derived islet cell therapy) as early as 2026; FDA INTERACT meeting supports GMP master cell bank.
- Enrolling GLEAM (SC291 in autoimmune) & VIVID (SC262 in B-cell malignancies); data expected 2025; IND for SG299 in vivo CAR T as early as 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000177012125000009/0001770121-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000177012125000009/sana-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001770121-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer